Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1452W HIGH $10.10
Volume
2.95 K
Value Traded
56.27 K
Short % Float
6.9%
+9.06%Week
-12.16%1 Month
-22.99%3 Month
-1.81%6 Month
-95.39%5 Year
-99.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
18.41 M
EPS (TTM)
-10.89
P/E Ratio
-
Ent. Value
13.39 M
Total Shares
2.83 M
Float Shares
1.52 M
Insiders
46.22%
Institutions
1.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LFWD Catalyst Timeline
Dated clinical, regulatory and corporate events for Lifeward Ltd.
Past FDA Catalysts and PDUFA Decisions
How LFWD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Lifeward Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LFWD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ReWalk | spinal cord injury mobility | 2026-05-04 | 3%; 0.3%; zero fractures reported in Germany since 2018; 97 users trackedRead More | Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered ExoskeletonRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rose Keith DaleOfficer (Chief Medical Officer) | Grant/Award | 15,000 17,083 held | $0.00 | 05/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LFWD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LFWD for Q2 2026. | ||||
LFWD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LFWD ranks across every disease it competes in
Competitive Position is a premium feature
See how LFWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLFWD News
LFWDPeer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
A recent peer-reviewed study published in the Internet Journal of Allied Health Sciences highlights the effectiveness of Lifeward's ReWalk exoskeleton for individuals with chronic spinal cord injuries. The study found significant improvements in daily activity performance, satisfaction, and reduced pain compared to traditional wheelchair use. All participants successfully completed kitchen tasks, and many reported enhanced bowel and bladder function. This evidence supports the clinical value and potential for wider adoption of the ReWalk technology.
Read more →LFWD▲ +6%on this news
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Lifeward Ltd. has released an updated investor presentation that outlines its strategy for scaling its rehabilitation platform and enhancing its distribution network. The presentation showcases the company's recent commercial performance and product development pipeline, including a strategic partnership with Oramed Pharmaceuticals. Lifeward aims to diversify its biomedical offerings beyond rehabilitation, targeting high-value therapeutic platforms.
Read more →LFWD▼ -5.9%on this news
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Lifeward Ltd. has appointed Josh Hexter as Interim CEO and Rami Aviram as CFO, effective September and November 2026, respectively. This leadership transition follows the departure of Mark Grant, who will assist during the transition. Lifeward is experiencing significant revenue growth and aims to scale its rehabilitation business further.
Read more →LFWD▼ -5.6%on this news
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Lifeward Ltd. reported a 16% revenue increase to $6.6 million for Q2 2026, marking its strongest quarterly performance since late 2024. The company's balance sheet was strengthened with a proforma cash balance of approximately $11 million. Despite these gains, Lifeward faced an increased net loss of $11.5 million, attributed to non-cash charges. The company continues to execute its capital-efficient distribution strategy and launched a pilot program with Ottobock Care to enhance access to its products.
Read more →LFWDLifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
Lifeward Ltd. announced it will report its second quarter 2026 financial results on August 14, 2026. The company, known for its neurorehabilitation products, is evolving into a diversified biomedical firm. Lifeward's pipeline includes the ORMD-0801 oral insulin candidate aimed at addressing diabetes. A press release will be issued prior to the report, but no conference call will be held.
Read more →LFWDLifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Lifeward has launched a pilot program with Ottobock Care to improve access to the ReWalk 7 Personal Exoskeleton. This six-month initiative aims to enhance awareness and support for patients with spinal cord injuries across the U.S. The collaboration leverages Ottobock's clinical expertise and patient care infrastructure to facilitate training and follow-up for users.
Read more →LFWDLifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Lifeward Ltd. has secured up to $11.2 million in strategic financing to enhance its commercial expansion. The funding includes $5.6 million in senior secured convertible notes, with an additional $5.6 million contingent on achieving specific commercial milestones. This financing is part of a broader strategy to strengthen Lifeward's reimbursement-backed distribution model and advance its product portfolio.
Read more →LFWDLifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Lifeward has appointed Dr. Keith D. Rose as Chief Medical Officer to enhance its neurorehabilitation portfolio and biomedical platform. Dr. Rose, with over 30 years of experience in rehabilitation medicine and neuroscience, will lead the company's global medical strategy. His prior roles have significantly contributed to Lifeward's medical affairs and strategic initiatives.
Read more →LFWDLifeward Reports First Quarter 2026 Financial Results
Lifeward Ltd. reported its financial results for Q1 2026, highlighting a successful strategic transaction with Oratech that brought $10 million in financing. The company noted a decrease in total revenue by 22% year-over-year, alongside a significant rise in operating expenses due to one-time charges related to the acquisition. Despite these financial challenges, Lifeward has managed to decrease its operating cash burn and has improved its operational efficiencies as it prepares for upcoming product trials and growth in neurorehabilitation technologies.
Read more →LFWDLifeward to Report First Quarter 2026 Financial Results on May 15, 2026
Lifeward Ltd. will announce its first quarter 2026 financial results on May 15, 2026. Following the announcement, CEO Mark Grant and CFO Almog Adar will host a conference call to discuss the results. Lifeward is known for its advanced neurorehabilitation technologies and is expanding into new therapeutic platforms, including oral delivery of biologic drugs.
Read more →LFWDLifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Lifeward presented new data on the ReWalk powered exoskeleton at the ASIA 2026 conference, highlighting a significant decline in lower extremity fractures among users. The study showed a fracture prevalence of just 3% since 2013, with zero fractures reported in Germany since 2018. These findings reinforce the safety profile of ReWalk and support its adoption for spinal cord injury mobility.
Read more →LFWDLifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. has finalized its strategic partnership with Oramed Pharmaceuticals, enhancing its position in the biomedical innovation sector. The partnership includes access to $47 million in capital, with an immediate $10 million drawdown. This collaboration is expected to pave the way for profitability and expand Lifeward's technological capabilities.
Read more →LFWD▼ -11.1%on this news
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
Lifeward Ltd. reported its fourth quarter and full year financial results for 2025, showcasing a strategic transition towards a diversified biomedical innovation company. The company received shareholder approval for a transformative deal with Oramed to acquire its POD™ technology, while also announcing the acquisition of powered upper-body exoskeleton technology. Despite a revenue decline of 33% in Q4 2025, Lifeward improved operational efficiency and expanded reimbursement coverage for its existing products, positioning itself for positive cash flow in 2026.
Read more →LFWDLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Lifeward has received shareholder approval to finalize a strategic partnership with Oramed Pharmaceuticals, which will enhance its position as a diversified biomedical company. This partnership allows Lifeward to integrate Oramed's POD™ oral delivery technology, potentially transforming treatment approaches for chronic diseases. The agreement also provides Lifeward access to approximately $47 million in capital to support its growth and profitability goals.
Read more →LFWD▲ +5.2%on this news· ran to +16% by day 3shared move
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lifeward Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, confirming that its stock maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days. The Nasdaq Listing Qualifications Staff has now closed the matter regarding the prior bid price deficiency. Lifeward is recognized for its innovative medical technologies aimed at transforming the lives of those with physical limitations or disabilities, allowing it to continue trading on the Nasdaq Capital Market.
Read more →LFWDLifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Lifeward Ltd. announced that it will report its fourth quarter and full year 2025 financial results on March 18, 2026. Company executives will host a conference call to discuss these results, which can be accessed by analysts and investors via multiple channels. Lifeward is recognized for its innovative medical technologies that aim to improve the lives of individuals with physical limitations. The company’s commitment to innovation is highlighted through their range of products designed for rehabilitation.
Read more →LFWD▼ -8.4%on this news· ran to -20% by day 3
Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
Lifeward Ltd. has partnered with Shirley Ryan AbilityLab to launch specialized clinics aimed at enhancing access to the ReWalk Personal Exoskeleton for individuals with spinal cord injuries. This collaboration, starting in the second quarter of 2026, will streamline the evaluation process and provide training and support for patients. The initiative is expected to promote greater independence and improved health outcomes for users.
Read more →LFWD▲ +20.2%on this news· ran to +35% by day 3shared move
Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
Lifeward Ltd. has announced its acquisition of technology assets from Skelable Ltd., including a powered upper body exoskeleton designed to assist stroke survivors. The acquisition, valued at $480,000, aims to expand Lifeward's portfolio and enhance its position in the neuro-rehabilitation market. The device is expected to launch commercially within 18 to 24 months, supporting patients in regaining functional movement.
Read more →LFWD▼ -18.2%on this newsshared move
Lifeward Announces Reverse Share Split
Lifeward Ltd. announced a 1-for-12 reverse share split effective February 24, 2026, following shareholder approval. This move aims to increase the per share price to meet Nasdaq listing standards. The company will also raise its authorized share capital to 100 million shares. The reverse split will adjust outstanding warrants and stock options proportionately.
Read more →LFWDLifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Lifeward's ReWalk Personal Exoskeleton is now covered by Aetna, joining Humana and UnitedHealthcare in providing Medicare Advantage coverage. This expansion allows approximately 16 million beneficiaries access to the device, which is recognized as medically necessary for individuals with spinal cord injuries. The decision is seen as a significant step in enhancing rehabilitation technology access.
Read more →About Lifeward Ltd.
Headquarters2 CABOT ROAD, HUDSON, MA, 01749
BIOPHARMAWATCH ELITE PLUS
Trade the next LFWD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime